AU2004261267B9 - Pyridyl derivatives and their use as therapeutic agents - Google Patents

Pyridyl derivatives and their use as therapeutic agents Download PDF

Info

Publication number
AU2004261267B9
AU2004261267B9 AU2004261267A AU2004261267A AU2004261267B9 AU 2004261267 B9 AU2004261267 B9 AU 2004261267B9 AU 2004261267 A AU2004261267 A AU 2004261267A AU 2004261267 A AU2004261267 A AU 2004261267A AU 2004261267 B9 AU2004261267 B9 AU 2004261267B9
Authority
AU
Australia
Prior art keywords
hydrogen
group
alkyl
independently selected
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004261267A
Other languages
English (en)
Other versions
AU2004261267A1 (en
AU2004261267B2 (en
Inventor
Melwyn Abreo
Heinz W. Gschwend
Daniel F. Harvey
Cindy J. Hudson
Rajender Kamboj
Vishnumurthy Kodumuru
Mikhail A. Kondratenko
Wenbao Li
Shifeng Liu
Vandna Raina
Mehran Seid Bagherzadeh
Shaoyi Sun
Serguei Sviridov
Chi Tu
Michael D. Winther
Zaihui Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of AU2004261267A1 publication Critical patent/AU2004261267A1/en
Publication of AU2004261267B2 publication Critical patent/AU2004261267B2/en
Application granted granted Critical
Publication of AU2004261267B9 publication Critical patent/AU2004261267B9/en
Priority to AU2009201861A priority Critical patent/AU2009201861A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2004261267A 2003-07-30 2004-07-29 Pyridyl derivatives and their use as therapeutic agents Ceased AU2004261267B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009201861A AU2009201861A1 (en) 2003-07-30 2009-05-11 Pyridyl derivatives and their use as therapeutic agents

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US49111803P 2003-07-30 2003-07-30
US49111603P 2003-07-30 2003-07-30
US49134003P 2003-07-30 2003-07-30
US60/491,340 2003-07-30
US60/491,116 2003-07-30
US60/491,118 2003-07-30
PCT/US2004/024657 WO2005011656A2 (en) 2003-07-30 2004-07-29 Pyridyl derivatives and their use as therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009201861A Division AU2009201861A1 (en) 2003-07-30 2009-05-11 Pyridyl derivatives and their use as therapeutic agents

Publications (3)

Publication Number Publication Date
AU2004261267A1 AU2004261267A1 (en) 2005-02-10
AU2004261267B2 AU2004261267B2 (en) 2009-02-12
AU2004261267B9 true AU2004261267B9 (en) 2009-04-09

Family

ID=34119804

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004261267A Ceased AU2004261267B9 (en) 2003-07-30 2004-07-29 Pyridyl derivatives and their use as therapeutic agents
AU2009201861A Abandoned AU2009201861A1 (en) 2003-07-30 2009-05-11 Pyridyl derivatives and their use as therapeutic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009201861A Abandoned AU2009201861A1 (en) 2003-07-30 2009-05-11 Pyridyl derivatives and their use as therapeutic agents

Country Status (15)

Country Link
US (2) US7605161B2 (https=)
EP (2) EP2316825A1 (https=)
JP (1) JP4782008B2 (https=)
KR (1) KR20060036106A (https=)
AU (2) AU2004261267B9 (https=)
BR (1) BRPI0412352A (https=)
CA (1) CA2533900A1 (https=)
EC (1) ECSP066312A (https=)
ES (1) ES2397389T3 (https=)
IL (1) IL173398A0 (https=)
MA (1) MA28008A1 (https=)
NO (1) NO20060972L (https=)
SG (1) SG145700A1 (https=)
TN (1) TNSN06036A1 (https=)
WO (1) WO2005011656A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
MXPA06001202A (es) * 2003-07-29 2006-08-31 Xenon Pharmaceuticals Inc Derivados piridilo y su uso como agentes terapeuticos.
WO2006004200A1 (ja) * 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
AR051091A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580762A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286648A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1827438B2 (en) * 2004-09-20 2014-12-10 Xenon Pharmaceuticals Inc. Piperazin derivatives for inhibiting human stearoyl-coa-desaturase
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
MX2007005205A (es) 2004-10-29 2007-05-11 Kalypsys Inc Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
AU2005311534B2 (en) * 2004-12-03 2011-02-17 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as H3 antagonists
WO2006125180A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperazine derivatives and their uses as therapeutic agents
WO2007044085A2 (en) * 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
WO2006125179A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1940815B1 (en) 2005-10-25 2018-08-15 Kalypsys, Inc. Salts of modulators of ppar and methods of treating metabolic disorders
EP1966183A4 (en) * 2005-12-20 2010-12-29 Merck Frosst Canada Ltd HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE
WO2007092435A2 (en) 2006-02-07 2007-08-16 Wyeth 11-beta hsd1 inhibitors
WO2007136746A2 (en) * 2006-05-19 2007-11-29 Xenon Pharmaceuticals Inc. Macrocyclic compounds and their uses as stearoyl-coa desaturase
WO2007143597A2 (en) 2006-06-05 2007-12-13 Novartis Ag Organic compounds
JP2010501567A (ja) 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
US20080182851A1 (en) * 2006-11-20 2008-07-31 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2008096746A1 (ja) 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited スピロ化合物およびその用途
DK2142529T3 (da) 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
ATE488499T1 (de) 2007-08-08 2010-12-15 Graceway Pharmaceuticals Llc Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen daraus
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
MX2010010471A (es) 2008-03-26 2010-10-20 Daiichi Sankyo Co Ltd Derivado de tetrahidroisoquinolina novedoso.
WO2010028761A1 (de) * 2008-09-09 2010-03-18 Sanofi-Aventis 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren
WO2010075356A1 (en) * 2008-12-23 2010-07-01 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
CA2750564A1 (en) 2009-02-17 2010-08-26 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CN102388052A (zh) * 2009-04-01 2012-03-21 诺瓦提斯公司 调节硬脂酰基-CoA去饱和酶的螺环衍生物
GB0907425D0 (en) * 2009-04-29 2009-06-10 Glaxo Group Ltd Compounds
EP2459568A4 (en) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd NEW SPIRO COMPOUNDS AS AN INHIBITORS OF STEAROYL COENZYME A DELTA 9 DESATURASE
EP2475367A1 (en) 2009-09-10 2012-07-18 Centre National De La Recherche Scientifique NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
HRP20170507T1 (hr) 2011-06-22 2017-06-02 Purdue Pharma Lp Trpv1 antagonisti uključujući dihidroksi supstituente i njihove uporabe
BR112014029365A2 (pt) 2012-05-22 2017-06-27 Hoffmann La Roche inibidores seletivos de células indiferenciadas
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
MX2021005688A (es) * 2018-11-14 2021-07-07 Allinky Biopharma Compuestos de piridina sulfonamida para el tratamiento contra afecciones relacionadas con interleucina 1 beta.
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007527A1 (en) * 1987-04-03 1988-10-06 The Upjohn Company Amino-9,10-secosteroids
WO1988008424A1 (en) * 1987-04-27 1988-11-03 The Upjohn Company Pharmaceutically active amines
EP0385350A1 (en) * 1989-03-01 1990-09-05 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
WO2001068619A1 (en) * 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
WO2001096327A1 (en) * 2000-06-01 2001-12-20 Glaxo Group Limited BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS
EP1180514A1 (en) * 1999-04-09 2002-02-20 Meiji Seika Kaisha Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
EP1243268A1 (en) * 1999-12-14 2002-09-25 Nippon Shinyaku Co., Ltd. Medicinal composition
WO2002081453A1 (fr) * 2001-04-04 2002-10-17 Laboratoires Fournier Sa Hiohydantoïnes et leur utilisation dans le traitement du diabete
WO2002088093A1 (en) * 2001-03-09 2002-11-07 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
WO2003045921A1 (en) * 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
AU2003221786A1 (en) * 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2003301436A1 (en) * 2002-10-17 2004-05-04 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2502824B2 (ja) 1991-03-13 1996-05-29 松下電器産業株式会社 平面型誘電体フィルタ
JP2503198Y2 (ja) 1991-06-17 1996-06-26 株式会社椿本チエイン 搬送方向に傾動可能なワ―ク回動ア―ムを具えたワ―ク搬送装置
AU761291B2 (en) * 1999-03-17 2003-05-29 Astrazeneca Ab Amide derivatives
EP1315831B8 (en) 2000-02-24 2010-09-01 Xenon Pharmaceuticals Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
US7232662B2 (en) 2000-09-26 2007-06-19 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
KR20040010713A (ko) 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
WO2003037862A1 (en) * 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Amide derivatives and drugs
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
OA12793A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase.
DE60326436D1 (en) 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
JP2004203871A (ja) * 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
MXPA06001202A (es) * 2003-07-29 2006-08-31 Xenon Pharmaceuticals Inc Derivados piridilo y su uso como agentes terapeuticos.
CN1829701A (zh) * 2003-07-30 2006-09-06 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007527A1 (en) * 1987-04-03 1988-10-06 The Upjohn Company Amino-9,10-secosteroids
WO1988008424A1 (en) * 1987-04-27 1988-11-03 The Upjohn Company Pharmaceutically active amines
EP0385350A1 (en) * 1989-03-01 1990-09-05 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
EP1180514A1 (en) * 1999-04-09 2002-02-20 Meiji Seika Kaisha Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
EP1243268A1 (en) * 1999-12-14 2002-09-25 Nippon Shinyaku Co., Ltd. Medicinal composition
WO2001068619A1 (en) * 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
WO2001096327A1 (en) * 2000-06-01 2001-12-20 Glaxo Group Limited BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS
WO2002088093A1 (en) * 2001-03-09 2002-11-07 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
WO2002081453A1 (fr) * 2001-04-04 2002-10-17 Laboratoires Fournier Sa Hiohydantoïnes et leur utilisation dans le traitement du diabete
WO2003045921A1 (en) * 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
AU2003221786A1 (en) * 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2003301436A1 (en) * 2002-10-17 2004-05-04 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts accession number 1977:601475 *
Jacobsen et al. (1990) J. Med. Chem. 33 (4): 1145-1151 *
Jacobsen et al. (1992) J. Med Chem. 35 (23): 4464-4472 *

Also Published As

Publication number Publication date
AU2004261267A1 (en) 2005-02-10
WO2005011656A3 (en) 2005-05-06
AU2004261267B2 (en) 2009-02-12
BRPI0412352A (pt) 2006-09-05
SG145700A1 (en) 2008-09-29
MA28008A1 (fr) 2006-07-03
KR20060036106A (ko) 2006-04-27
US8153636B2 (en) 2012-04-10
NO20060972L (no) 2006-05-02
US20060199802A1 (en) 2006-09-07
JP4782008B2 (ja) 2011-09-28
ECSP066312A (es) 2006-07-28
TNSN06036A1 (en) 2007-10-03
CA2533900A1 (en) 2005-02-10
WO2005011656A2 (en) 2005-02-10
JP2007500719A (ja) 2007-01-18
EP1651606A2 (en) 2006-05-03
IL173398A0 (en) 2006-06-11
US20100048584A1 (en) 2010-02-25
ES2397389T3 (es) 2013-03-06
AU2009201861A1 (en) 2009-06-04
AU2009201861A8 (en) 2009-06-11
EP1651606B1 (en) 2012-10-24
US7605161B2 (en) 2009-10-20
EP2316825A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
AU2004261267B9 (en) Pyridyl derivatives and their use as therapeutic agents
AU2004261249B2 (en) Pyridazine derivatives and their use as therapeutic agents
AU2004261250B2 (en) Pyridyl derivatives and their use as therapeutic agents
AU2004261268B2 (en) Piperazine derivatives and their use as therapeutic agents
EP1807085B1 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580781A1 (en) Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
AU2005329423A1 (en) Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580762A1 (en) Heterocyclic derivatives and their use as therapeutic agents
AU2005286653A1 (en) Pyridine derivatives for inhibiting human stearoyl-CoA-desaturase
MXPA06001203A (en) Pyridyl derivatives and their use as therapeutic agents

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired